Arctic Bioscience – funded to cash positive
Reading Time: 2 minutes Arctic Bioscience is now funded through a NOK 30 million loan facility. Strong 30% y/y growth in sales revenues in 2024 and prospects of continued strong growth in coming years. Psoriasis drug candidate HRO350 on track for 12 months readout end of
FISKARS CORPORATION: ACQUISITION OF OWN SHARES 13.01.2025
Reading Time: < 1 minute Stock Exchange Release 13.01.2025 at 18:30 EET/EEST FISKARS CORPORATION: ACQUISITION OF OWN SHARES 13.01.2025 Date 13.01.2025 Exchange transaction Buy Share class FSKRS Amount 2000 Average price/share 14.5861 EUR Highest price/share 14.6200 EUR Lowest price/share
ALEXANDRIA GROUP OYJ: ACQUISITION OF OWN SHARES 13.01.2025
Reading Time: < 1 minute ALEXANDRIA GROUP OYJ NOTIFICATION 13.01.2025 at 18:30 EET ALEXANDRIA GROUP OYJ: ACQUISITION OF OWN SHARES 13.01.2025 Date 13.01.2025 Exchange transaction Buy Share class ALEX Amount 200 Average price/share 8,8500 EUR Highest
OncoZenge AB has entered into a non-binding agreement with the intention to partner with Molteni Farmaceutici for commercialization of BupiZenge™ in Europe
Reading Time: 3 minutes STOCKHOLM, SWEDEN – January 13, 2025 – OncoZenge AB (publ) (“OncoZenge” or the “Company”), announces that the Company has entered into a non-binding agreement with the intention to partner with pharmaceutical leader Molteni Farmaceutici (“Molteni”) regarding exclusive rights to commercialization of BupiZenge™
Arctic Bioscience – Primary insiders participating in convertible loan facility
Reading Time: 2 minutes Reference is made to the stock exchange release from earlier today, 13th January 2025, regarding new funding, including a convertible loan facility of NOK 15 million. The following primary insiders, or closely related companies to primary insiders, are a part of
Nordea Bank Abp: Repurchase of own shares on 13.01.2025
Reading Time: < 1 minute Nordea Bank AbpStock exchange release – Changes in company’s own shares13.01.2025 at 22.30 EET Nordea Bank Abp (LEI: 529900ODI3047E2LIV03) has on 13.01.2025 completed repurchases of own shares (ISIN: FI4000297767) as follows: Trading venue (MIC Code) Number of shares Weighted average
SciBase announces outcome of directed issue and preliminary outcome of rights issue
Reading Time: 7 minutes SciBase Holding AB (”SciBase” or the ”Company”) today announces the preliminary outcome of the capital raise, consisting of a rights issue of units of approximately SEK 59.3 million (the “Rights Issue”) and a directed issue of units, deviating from existing shareholders’ preferential
Tele2 announces changes to the Group Leadership Team
Reading Time: 2 minutes Stockholm – Tele2 AB (“Tele2”) (Nasdaq Stockholm: TEL2 A and TEL2 B) announces that Kim Hagberg, Executive Vice President, Chief Operations, will leave her position effective from today. Kim joined Tele2 in 2013 and has held many positions over the
Mandatum plc: Disclosure Under Chapter 9 Section 5 of the Securities Market Act (Altor Fund Manager AB)
Reading Time: 2 minutes Mandatum Plc, Stock exchange release, 13 January 2025 at 20:00 EET Mandatum plc (Business ID 3355142-3) has received a notification, pursuant to Chapter 9, Section 5 of the Finnish Securities Markets Act, that the breakdown of Altor Fund Manager AB’s (registration
disposing remaining Castellum shares to its parent
Reading Time: < 1 minute Akelius Residential Property AB has agreed to sell its remaining 51,800,760 shares in Castellum. The buyer is Akelius Apartments Limited,and the agreed price is SEK 130 per share. Akelius Residential Property AB does not hold any shares in Castellum after